Priority Driven Collaborative Cancer Research Scheme Priority Driven (PDCCRS) 2016: Collaborative Lowy Cancer Reprogramming the Tumour Cancer Cancer Research Centre, Microenvironment with the $247,983.25 04/04/2017 36 Sydney 2052 Australia Research University of NSW use of Nanomedicines for the Scheme Treatment of Pancreatic Cancer: ID1126736. Ref: Priority Driven Collaborative Priority Driven Cancer Research Scheme Council of the Collaborative (PDCCRS) 2016: Dnmt3a loss Cancer Queensland Cancer contributes to disease $100,000.00 04/04/2017 24 Herston 4006 Australia Institute of Medical Research progression in Research Scheme myeloproliferative neoplasm: ID1124096. Ref: CA-G1516/77 Priority Driven Collaborative Priority Driven Cancer Research Scheme Collaborative (PDCCRS) 2016: Differential Cancer Macquarie Cancer effects of MAPK inhibition on $2,078.50 04/04/2017 24 Macquarie University 2109 Australia University Research immune activity determine Scheme melanoma response: ID1123911. Ref: CA-G1516/78 Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2016: Phase II Priority Driven clinical trial of the PARP Collaborative Cancer University of inhibitor, olaparib, in HR- The University of Cancer $300,000.00 10/04/2017 36 2006 Australia Sydney deficient advanced breast Sydney Research and ovarian cancer in Scheme women without inherited BRCA1 or BRCA2 mutations: ID1128740. Ref: CA-G1516/71 Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2016: AUTO-CHECK Priority Driven study: Molecular Collaborative Cancer Australian National determinants of autoimmunity Cancer $574,009.00 10/04/2017 36 Acton 2601 Australia University and immune related adverse Research events in advanced cancer Scheme patients treated with immune checkpoint inhibitors: ID1130330. Ref: CA-G1516/74 Priority Driven Collaborative Priority Driven Cancer Research Scheme Collaborative Cancer University of (PDCCRS) 2016: High Precision The University of Cancer $597,325.50 28/04/2017 36 2006 Australia Sydney Radiotherapy: Dual Cardiac Sydney Research and Respiratory Motion Scheme Management: ID1123068. Ref:
Cancer Australia Priority Driven Collaborative Cancer Research Scheme Lowy Cancer Research Centre, University of NSW Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2016: Reprogramming the Tumour Microenvironment with the use of Nanomedicines for the Treatment of Pancreatic Cancer: ID1126736. Ref: $247,983.25 04/04/2017 36 Sydney 2052 Cancer Australia Priority Driven Collaborative Cancer Research Scheme Council of the Queensland Institute of Medical Research Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2016: Dnmt3a loss contributes to disease progression in myeloproliferative neoplasm: ID1124096. Ref: CA-G1516/77 $100,000.00 04/04/2017 24 Herston 4006 Cancer Australia Priority Driven Collaborative Cancer Research Scheme Macquarie University Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2016: Differential effects of MAPK inhibition on immune activity determine melanoma response: ID1123911. Ref: CA-G1516/78 $2,078.50 04/04/2017 24 Macquarie University 2109 Cancer Australia Priority Driven Collaborative Cancer Research Scheme University of Sydney Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2016: Phase II clinical trial of the PARP inhibitor, olaparib, in HR- deficient advanced breast and ovarian cancer in women without inherited BRCA1 or BRCA2 mutations: ID1128740. Ref: CA-G1516/71 $300,000.00 10/04/2017 36 The University of Sydney 2006 Cancer Australia Priority Driven Collaborative Cancer Research Scheme Australian National University Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2016: AUTO-CHECK study: Molecular determinants of autoimmunity and immune related adverse events in advanced cancer patients treated with immune checkpoint inhibitors: ID1130330. Ref: CA-G1516/74 $574,009.00 10/04/2017 36 Acton 2601 Cancer Australia Priority Driven Collaborative Cancer Research Scheme University of Sydney Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2016: High Precision Radiotherapy: Dual Cardiac and Respiratory Motion Management: ID1123068. Ref: $597,325.50 28/04/2017 36 The University of Sydney 2006
grants_reporting_20170703.docx